Literature DB >> 15075985

The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma.

Javier P Gisbert1, Luisa García-Buey, Reyes Arranz, Carlos Blas, Inmaculada Pinilla, Sam Khorrami, Agustín Acevedo, María J Borque, José M Pajares, José M Fernández-Rañada, Ricardo Moreno-Otero.   

Abstract

AIM: Lymphomagenesis is a multifactorial process in which genetic, environmental and infectious factors can be involved. The aim of the present study was to assess the prevalence of hepatitis C virus (HCV) infection among patients with non-Hodgkin's lymphoma (NHL), and to compare it with that of a control group of voluntary blood donors.
METHODS: All consecutive patients with a histological diagnosis of NHL from January 1996 to December 2001 were included in this prospective study. As control group for HCV infection, voluntary blood donors recruited over the same time period from the same geographical area were considered. The presence of anti-HCV antibodies was investigated by ELISA-II and RIBA-II, and viraemia (HCV RNA) was tested by using a polymerase chain reaction (PCR). HCV genotyping was also performed.
RESULTS: Ninety-nine patients (mean age 48 years) with NHL were diagnosed during the study period. Histological classification of NHL was high-intermediate grade (63 patients), and low grade (36 patients). Immunophenotype distribution was type B (86 patients) and type T (13 patients). Seven of the 99 NHL patients (7%) were infected with HCV (both using serology and PCR), five of them with immunophenotype B and two with immunophenotype T. The prevalence of HCV infection according to NHL phenotype was 5.8% in B-cell NHL and 15.4% in T-cell NHL. The HCV genotype was 1b in six cases, and 3a in one. In voluntary blood donors (mean age 45 years), HCV infection was detected in 517/55 587 (0.93%). Therefore, HCV infection was more frequent in NHL patients than in controls (odds ratio = 8.1; 95% CI = 3.7-17.6). The odds ratio for the association of HCV and B-cell NHL was 6.2 (95% CI = 2.5-15.3), and for T-cell NHL 16.4 (95% CI = 3.7-72.8).
CONCLUSION: The prevalence of HCV infection in patients with NHL (both B- and T-type) is higher than that observed in controls, suggesting a role of HCV in lymphoma aetiopathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075985     DOI: 10.1097/00042737-200402000-00003

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer.

Authors:  Clodoveo Ferri; Marco Sebastiani; Dilia Giuggioli; Michele Colaci; Poupak Fallahi; Alessia Piluso; Alessandro Antonelli; Anna Linda Zignego
Journal:  World J Hepatol       Date:  2015-03-27

2.  Management of chronic hepatitis C: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

Review 3.  Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.

Authors:  Gabriele Pozzato; Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Francesca Zorat; Giulia Moratelli; Pietro Bulian; Diego Serraino; Valter Gattei
Journal:  World J Hepatol       Date:  2016-01-18

Review 4.  Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy.

Authors:  Syed Tasleem; Gagan K Sood
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

Review 5.  Hepatitis C virus and non-Hodgkin's lymphomas: A minireview.

Authors:  Hussein Khaled; Fouad Abu-Taleb; Rasha Haggag
Journal:  J Adv Res       Date:  2016-12-12       Impact factor: 10.479

6.  Evaluation of HTLV-I and HCV Prevalence in Non-Hodgkin's Lymphoma.

Authors:  Maryam Rastin; Ali Reza Khoee; Nafiseh Tabasi; Akram Sheikh; Saeed Ziaolhagh; Elham Esmaeeli; Shahrzad Zamani; Mahdieh Khazaee; Mahmoud Mahmoudi
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.